Tumor development is angiogenesis dependent, and vascular endothe 11*1 growth factor (VEGF) is a key growth factor in this process. We demonstrate that high expression of VEGF mRNA in 55 superficIal blad der cancers was associated with earlier recurrence (P = 0.001; hazard ratio, 3.09) and progression to a more invasive phenotype (P = 0.02; hazard ratio, 533). VEGF mRNA expression correlated with protein although in cases without high p53 protein expression, high VEGF mRNA also predicts a poor prognosis. The relationship between VEGF and early twnor recurrence suggests that seeding via angiogenesis may be a major mechanism in the pathogenesis of recurrence. These studies indicate that VEGF can predict the behavior of superfidal bladder tumors and is a therapeutic target for intravesical therapy.
Introduction
Angiogenesis, as quantitated by vascular density, is an independent prognostic tumor marker in several tumor types (1), and VEGF3 is a major factor in this process (2) . High vascular density is associated with a poor prognosis in bladder cancer (3, 4) , suggesting that VEGF may give prognostic information in these tumors. Clinical and mo lecular evidence point to different developmental pathways for super ficial (stage Ta and T1) and muscle invasive (stage T24) bladder cancer, and we have previously demonstrated differential up-regula tion of VEGF mRNA in superficial disease (5) . Over 50% of stage T1 bladder cancers recur within 12 months, and 30% progress to muscle invasion with a poor prognosis, despite treatment (6) . The mecha nisms leading to relapse and stage progression are poorly understood but are particularly relevant to well and moderately differentiated (G1 and G2, respectively) T1 tumors, which account for a large proportion of bladder cancer. This highly heterogeneous group of tumors exhibits variable clinical behavior (7), making determination of the risk of relapse and stage progression difficult. Mutations of the p53 tumor suppressor gene indicate a poor prognosis in these tumors (8, 9) and have been implicated in the regulation of VEGF expression in cell lines. Here we show that high VEGF mRNA expression strongly indicates a poor prognosis in stage T1 bladder cancer and that over expression of p53 protein, detected by immunochemistry, is related to VEGF up-regulation, which may, therefore, be one of the key down stream pathways in vivo for the adverse effects of mutations of the gene. The study demonstrates that the endothelial-specific angiogenic factor VEGF is a major determinant of biological behavior of early bladder cancer, indicating the possibility for treatment using anti VEGF strategies.
Materials and Methods
Patients and Sample Collection. Primary superficial transitional cell car cinomas of the bladder were obtained from 94 patients undergoing transure thral bladder cancer resection at The Churchill Hospital. Twenty-nine speci mens of macroscopically normal bladder were obtained from patients undergoing surgery for bladder cancer (n = 22) or from cadaveric organ donors at the time of donor nephroureterectomy (n = 7).
RNAand Protein Preparation.RNAwas preparedaccordingto the method of Chomczynski and Saachi (10) . All RNA samples were run on a 1% agarose gel (under RNase-free conditions), and the concentrations were meas ured spectrophotometrically prior to RNase protection analysis. Tumor protein cytosols were prepared in HEPES buffer as described previously (1 1).
RNA was extracted from 55 tumors (37 male and 18 female patients) for which follow-up was known. The median age was 73 years old (range, 37â€"90 years), and the median follow-up was 24 months (minimum, 6 months probes, gives rise to a 150-bp protected fragment, whereas a l20-bp protected fragment corresponded to the antisense GAPDH riboprobe hybridized to endogenous GAPDH. All signals were normalized to the external control formed by hybridization of the sense and antisense GAPDH riboprobes (12) and were expressed relative to a positive control run on all electrophoresis gels. Immunohistochemistry. Five-@.tm paraffin sections were available for all 55 T1G1and T1G2bladder tumors that had VEOF mRNA quantified. Sections were analyzed for p53 and EGFr protein expression using an avidin-biotin complex immunoperoxidase technique ( I3). All steps were performed at room temperature. In brief, following deparaffinization endogenous peroxidase was blocked by immersing sections in methanol with 0.3% hydrogen peroxide, followed by incubation in 5% normal human serum for 30 mm. Following high pressure antigen retrieval, tissue sections were incubated for 2 h with the primary antibody. PAbl8Ol, at a concentration of 200 ng/ml (Oncogene Science, Inc., Manhassett, NY), was used as the primary antibody for p53
analysis, whereas NCL-EGFr, at S @g/ml (Novacastra Laboratories, Ltd., Peterborough, UK), was used for the analysis of EGFr. Breast cancer speci mens with high expression of either p53 or EGFr were used as positive controls, and a negative control antibody of the same isotype was run for all sections. Sections were incubated with secondary biotinylated goat anti-mouse antibody for 1 h at a 1:100 dilution (Dako Ltd., High Wycombe, UK) and with avidin-biotin-peroxidase complexes for 1 h (Dako Ltd., High Wycombe, UK).
Diaminobenzidine was the chromogen, and sections were counterstained in hematoxylin. All sections were washed twice for 3 mm in PBS between incubations. Sections were reviewed independently by two investigators. Tu mors with p53 nuclear staining in over 20% of cells or strong EGFr membrane staining were considered positive for p53 and EGFr, respectively. The regions of strongest staining were analyzed. Statistics. All statistics was performed using Statview 4.5 (Abacus Con cepts, Berkeley, CA) or Stats 5.0 (Stata Corp. TX). The effect of VEGF and p53 on time to recurrence and stage progression was assessed using Cox proportional hazards regression (Table 2 ). Regression analysis was also per formed on characteristics of the tumor (multifocality, morphology, grade, and
EGFr status) and patient (age, sex, and smoking history). In multivariate analysis, VEGF, pS3, tumor multifocality, and morphology were analyzed. All other analyses and correlations were performed using a Mann-Whitney U test or Spearman's rank correlation, respectively.
Results
The Prognostic Significance of VEGF mRNA on Recurrence and Stage Progression in Stage T1 Bladder Cancer. Using RNase protection analysis, VEGF mRNA was quantified in 55 primary T1G1 and T1G, transitional cell carcinomas of the bladder and 12 normal bladder specimens (7 cadaveric organ donors and 5 patients undergoing surgery for bladder cancer; Fig. 1 ). There was a 300-fold variation in expression of VEGF mRNA in the tumors, with expression greater in tumors than normal bladder (P < 0.001; Table 1 ). VEGF mRNA was higher in tumors that recurred within 6 months (n = 28; P < 0.001) or that underwent stage progression to a muscle-invasive phenotype (n = 12; P = 0.02; Fig. 2 ).
The effect of VEGF mRNA on time to relapse and stage progres sion was assessed in univariate and multivariate analysis. Bladder tumors with VEGF mRNA levels above the median underwent earlier recurrence (P = 0.001; hazard ratio, 3.09; 95% CI, 1.54â€"6.20) and had a greater risk of stage progression to an invasive phenotype (P = 0.02; hazard ratio, 5.33; 95% CI, 1.16â€"24.4)than those express ing levels below the median (Fig. 2) . Similarly, VEGF mRNA as a continuous variable was significantly associated with time to tumor recurrence (hazard ratio, 1.1 1; 95% CI, 1.02â€"1.21;P = 0.01), and there was evidence that progression-free survival was shortened in patients with higher VEGF mRNA (hazard ratio, 1.14; 95% CI, 0.99â€"1.31; P = 0.06). Months since diagnosis Months since diagnosis The Relationship between VEGF mRNA and Protein. VEGF protein was higher in superficial bladder tumors compared to normal bladder (Table 1 ; P < 0.0001), although there was no difference between stages Ta and T1 (P = 0.32; Fig. 3 ). In both normal bladder However, the ratio of VEGF protein to mRNA was 4-fold greater in superficial tumors compared to normal bladder (Table 1 ; P = 0.004), suggesting that there is posuranscriptional regulation of VEGF in some tumors. The Relationship between Abnormal p53 Expression and VEGF. Expression of VEGF mRNA (n = 55) was 3-fold greater (P < 0.001; Table 1), and protein (n = 29) was 2-fold greater in tumors that were p53 positive compared with those that were p53 negative (n = 29; P = 0.02; Table 1; Fig. 3 ), although protein:mRNA ratios were the same (P = 0.78).
Interaction of High VEGF and Higji p53 with Recurrence and Stage Progression. VEGF mRNA was strongly related to earlier recurrence and stage progression. Similarly, overexpression of p53 protein (n = 14), as shown in other studies, was associated with a shorter time to recurrence (hazard ratio, 3.57; P = 0.001) and stage progression (hazard ratio, 3.19; P = 0.05). Tumors that expressed high VEGF mRNA and were p53 positive had the poorest prognosis with respect to early recurrence (P < 0.001; hazard ratio, 4.19; 95% CI, 2.00â€"8.84) and progression (P = 0.04; hazard ratio, 3.39; 95% CI, 1.09â€"10.6; Fig. 2) ; however, in p53-negative tumors, high expres sion of VEGF mRNA also resulted in increased risk of early recur rence compared to low VEGF expression (P = 0.06; hazard ratio, 2.10; 95% CI, 0.92â€"4.80; Fig. 2 ). This suggests an interaction of VEGF and p53 in determining bladder tumor behavior and indicates that VEGF may give additional prognostic information in p53-nega tive tumors.
In multivariate analysis, VEGF mRNA was an independent prog nostic factor for early recurrence (P = 0.02; hazard ratio, 1.12; 95% CI, 1.02â€"1.22) when allowing for tumor multifocality and morphol ogy (the most significant parameters in univariate analysis; Table 2 ), although the association between p53 and VEGF reduced the effect of VEGF when allowing for p53. 
Discussion
Although VEGF expression has been related to systemic metastasis via angiogenesis, a role in local tumor growth, invasion, and recur rence has not been demonstrated in patients. In this study, VEGF mRNA and protein expression are shown to correlate in T1G1 and T1G2 bladder cancer. The association between high VEGF levels in the tumors and a poor prognosis presents a means of determining the biological nature and behavior of this heterogeneous group, which could allow treatment to be tailored to individual patients.
The strong association between high VEGF mRNA expression and bladder tumor relapse (hazard ratio, 3.09; P = 0.001 for tumors with mRNA levels above the median) suggests a role for VEGF in the pathogenesis of recurrence. One mechanism for metachronous bladder tumor recurrence is the implantation of clones of cells that originate from the primary tumor (14) . Tumors with high VEGF expression may recur frequently by virtue of the survival advantage conferred upon malignant cells through an ability to implant and grow rapidly due to enhanced angiogenesis. Alternatively, the significant associa tion between tumor multifocality, earlier recurrence, and stage pro gression also demonstrated in the study (Table 2 ) supports a field change within the bladder, although no association between primary tumor VEGF mRNA expression and multifocality (n 55, P 0.56) was evident. The two theories of recurrence are not mutually exclu sive, and it is likely that both are probably involved in the pathogen esis.
The increased risk of stage progression associated with high VEGF (hazard ratio, 5.33; P = 0.02 for tumors with levels above the median) could result from the direct angiogenic effect of the growth factor as well as induction of proteolytic enzymes such as urokinase-type plasminogen activator in endothelial cells. Furthermore, although evidence is conflicting, VEGF may interfere with the immune re sponse to the tumor, facilitating invasion and stage progression (15, 16). The difference in VEGF protein:mRNA ratios between superficial bladder tumors and normal bladder may result from posttranscrip tional regulation through factors including the eukaryotic initiation factor 4e. This polypeptide facilitates translation by increasing bind ing efficiency of mRNA to the ribosome and has been demonstrated to induce malignant transformation and increased VEGF expression in vitro and in vivo (17, 18). High protein levels could equally represent the release of heparin-binding isoforms of VEGF from stores as the tumor invades, as has been suggested for basic fibroblast growth factor in bladder cancer (19) .
Abnormal expression of the p53 protein, as determined by immu nochemical methods, correlates with the presence of p53 mutations and a poor prognosis in bladder cancer (8, 9) . p53 regulates angio genesis (20) , partly through the angiogenesis inhibitor throm bospondin-l (21, 22) , and may have a role in the regulation of VEGF (23, 24) . The correlation between high VEGF and overexpression of the p.53 gene in stage T1 bladder cancer indicates this tumor suppres sor gene may be involved in regulation of the growth factor. Because VEGF protein:mRNA ratios were independent of p53 status, such regulation is likely to be pretranslational in these tumors. VEGF mRNA expression was related to prognosis irrespective of the p53 status, indicating the existence of p53-dependent and -inde pendent pathways of VEGF regulation in T1 bladder cancer, with each contributing to a poor prognosis. VEGF may, therefore, yield addi tional prognostic information in bladder tumors, in particular those that are p53 negative as shown by multivariate analysis.
Antineoplastic strategies directed against VEGF can reduce tumor growth and systemic spread in solid tumors (25, 26) , but a role in preventing local recurrence and stage progression has not been shown previously.
The needs for new treatments for bladder cancer make such strategies a therapeutic avenue worthy of study. Bladder cancer provides the ideal tumor, because the option of intravesical adminis tration allows prolonged contact between the agent and the abnormal epithelium. One candidate is suramin, an antitrypanosomal compound that antagonizes heparin-binding growth factors including VEGF (27, 28) and has a direct inhibitory effect upon bladder cancer cells (29) . Although moderately effective in the treatment of advanced prostatic cancer, the use of suramin has been limited due to side effects of systemic administration (30) . Reduced systemic toxicity associated with intravesical administration makes bladder cancer an attractive target for its antineoplastic effect (31).
This study places an angiogenic factor as a key regulator of local tumor behavior, providing evidence that it is a molecular marker of prognosis and adding an important new target for intravesical therapy.
